Drugs / Rituximab and Hyaluronidase Human
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04659044 | Apr 2021 → Mar 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma | Academic and Community Cancer Research United | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rituximab and Hyaluronidase Human | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04659044 ↗ |
| Known as | Rituximab hyaluronidase | “Rituximab hyaluronidase is a combination of rituximab and hyaluronidase.” NCT04659044 ↗ |
| Route | Subcutaneous | “rituximab and hyaluronidase human subcutaneously (SC) over 5 minutes” NCT04659044 ↗ |